Repare Therapeutics Stock

Repare Therapeutics Liabilities 2024

Repare Therapeutics Liabilities

41.82 M USD

Ticker

RPTX

ISIN

US7602731025

WKN

A2P7AV

In 2024, Repare Therapeutics's total liabilities amounted to 41.82 M USD, a -50.57% difference from the 84.6 M USD total liabilities in the previous year.

Repare Therapeutics Aktienanalyse

What does Repare Therapeutics do?

Repare Therapeutics Inc is a biotechnology company specializing in the development of precision medicines for the treatment of cancer. It was founded in 2016 by four leading scientists and is headquartered in Montreal, Canada. The company utilizes an innovative and unique approach called CRISPR-Cas9 to identify and target genetic mutations in cancer cells. The history of Repare Therapeutics Inc stems from a collaboration among renowned cancer researchers. In 2016, the founders, who already had extensive experience in drug development, pooled their resources to create a new generation of cancer therapies. Using the innovative CRISPR-Cas9 system, they were able to specifically identify genetic alterations in cancer cells and significantly reduce tumor burden. Since its inception, the company has formed strong partnerships and successfully raised capital to continue its research and development. Repare Therapeutics has a unique business model focused on developing precision medicine for patients with specific types of cancer. The company combines CRISPR-Cas technology and machine learning to identify genetic mutations in cancer cells and correlate them with an extensive dataset of available clinical studies. This systematic approach allows for faster and more precise identification of suitable target molecules that may serve as potential therapy options for cancer. Repare Therapeutics specializes in quickly and efficiently developing molecules that target these target molecules and advancing them through clinical trials. The company distributes its precision medicines in three different sectors: oncology, therapeutics, and research. The oncology sector specializes in the development of precision medicines for the treatment of cancer. The therapeutics sector offers solutions for the medical care of patients through the development of novel therapies. The research department focuses on developing new precision medicines and advancing innovations in cancer research. Repare Therapeutics offers various products tailored to the needs of cancer patients. The CRISPR-Cas9 technology is being used to advance multiple clinical programs aimed at regulating gene expression in tumor cells and enhancing the effectiveness of cancer therapies. The company's flagship product, RP-3500, is a precision medicine specifically targeted against a gene called KRAS, which plays a crucial role in many types of cancer. The medication has demonstrated strong efficacy in clinical trials and is currently in Phase 1 studies. In summary, Repare Therapeutics Inc is an innovative biotechnology company specializing in the development of precision medicines against cancer. The use of CRISPR-Cas9 technology in combination with machine learning allows for faster identification of suitable target molecules that may serve as potential therapy options for cancer. The company offers various precision medicines that benefit cancer patients. With its numerous research programs and clinical trials, Repare Therapeutics is poised to become a leading player in cancer treatment and research. Repare Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Repare Therapeutics's Liabilities

Repare Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Repare Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Repare Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Repare Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Repare Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Repare Therapeutics stock

What is the level of liabilities of Repare Therapeutics this year?

Repare Therapeutics has a debt balance of 41.82 M USD this year.

What were the liabilities of Repare Therapeutics compared to the previous year?

The liabilities of Repare Therapeutics have increased by -50.57% dropped compared to the previous year.

What are the consequences of high debt for investors of Repare Therapeutics?

High liabilities can pose a risk for investors of Repare Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Repare Therapeutics?

Low liabilities mean that Repare Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Repare Therapeutics affect the company?

An increase in liabilities of Repare Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Repare Therapeutics affect the company?

A decrease in the liabilities of Repare Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Repare Therapeutics?

Some factors that can influence the liabilities of Repare Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Repare Therapeutics so important for investors?

The liabilities of Repare Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Repare Therapeutics take to modify the liabilities?

To change its liabilities, Repare Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Repare Therapeutics pay?

Over the past 12 months, Repare Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Repare Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Repare Therapeutics?

The current dividend yield of Repare Therapeutics is .

When does Repare Therapeutics pay dividends?

Repare Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Repare Therapeutics?

Repare Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Repare Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Repare Therapeutics located?

Repare Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Repare Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Repare Therapeutics from 12/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/4/2024.

When did Repare Therapeutics pay the last dividend?

The last dividend was paid out on 12/4/2024.

What was the dividend of Repare Therapeutics in the year 2023?

In the year 2023, Repare Therapeutics distributed 0 USD as dividends.

In which currency does Repare Therapeutics pay out the dividend?

The dividends of Repare Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Repare Therapeutics

Our stock analysis for Repare Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Repare Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.